The 1 analysts offering 12-month price forecasts for Poniard Pharmaceuticals Inc have a median target of 80.00, with a high estimate of 80.00 and a low estimate of 80.00. The median estimate represents a +99,900.00% increase from the last price of 0.08.
The current consensus among 1 polled investment analysts is to Hold stock in Poniard Pharmaceuticals Inc. This rating has held steady since February, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.12
Reporting Date Feb 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.